Anti-apolipoprotein A-1 autoantibodies are associated with immunodeficiency and systemic inflammation in HIV patients

Autor: Nathalie Satta, Sabrina Pagano, Fabrizio Montecucco, Baris Gencer, François Mach, Laurent Kaiser, Alexandra Calmy, Nicolas Vuilleumier, V. Aubert, J. Barth, M. Battegay, E. Bernasconi, J. Böni, H.C. Bucher, C. Burton-Jeangros, A. Calmy, M. Cavassini, M. Egger, L. Elzi, J. Fehr, J. Fellay, P. Francioli, H. Furrer, C.A. Fux, M. Gorgievski, H. Günthard, D. Haerry, B. Hasse, H.H. Hirsch, B. Hirschel, I. Hösli, C. Kahlert, L. Kaiser, O. Keiser, C. Kind, T. Klimkait, H. Kovari, B. Ledergerber, G. Martinetti, B. Martinez de Tejada, K. Metzner, N. Müller, D. Nadal, G. Pantaleo, A. Rauch, S. Regenass, M. Rickenbach, C. Rudin, P. Schmid, D. Schultze, F. Schöni-Affolter, J. Schüpbach, R. Speck, P. Taffé, P. Tarr, A. Telenti, A. Trkola, P. Vernazza, R. Weber, S. Yerly
Rok vydání: 2018
Předmět:
CD4-Positive T-Lymphocytes
Male
0301 basic medicine
Apolipoprotein B
autoantibodies
HIV Infections
030204 cardiovascular system & hematology
Systemic inflammation
0302 clinical medicine
Risk Factors
Odds Ratio
Prospective Studies
Prospective cohort study
Immunodeficiency
ddc:616
0303 health sciences
biology
apoptosis
virus diseases
Middle Aged
3. Good health
Infectious Diseases
RNA
Viral
Female
lipids (amino acids
peptides
and proteins)
medicine.symptom
Cardiology and Cardiovascular Medicine
Adult
Microbiology (medical)
Inflammation
Viremia
Cell Line
03 medical and health sciences
medicine
HIV
anti-apoA-1 IgG
apoptosis
autoantibodies
inflammation
Humans
ddc:576
030304 developmental biology
Apolipoprotein A-I
business.industry
Immunologic Deficiency Syndromes
Autoantibody
anti-apoA-1 IgG
HIV
Odds ratio
medicine.disease
030104 developmental biology
inflammation
Immunoglobulin G
Immunology
biology.protein
business
Biomarkers
Zdroj: Journal of Infection, Vol. 76, No 2 (2018) pp. 186-195
ISSN: 0021-9150
0163-4453
Popis: Objectives To determine the existence of autoantibodies against apolipoprotein A-1 (anti-apoA-1 IgG) in HIV patients and explore their association with biological features of HIV infection and different inflammatory biomarkers. We also evaluated their impact on CD4 + lymphocytes survival. Methods Anti-apoA-1 IgG plasma levels were assessed by ELISA in 237 HIV positive patients from a national prospective cohort with no current lipid-lowering therapy. Results 58% of patients were found positive for anti-apoA-1 IgG and were associated with lower CD4 + counts, but higher viremia and systemic inflammation. Logistic regression analyses indicated that high anti-apoA-1 IgG levels were associated with a 16-fold increased risk of displaying low CD4 + levels, independent of HIV RNA levels and treatment (adjusted Odds ratio [OR]:16.1, 95% Confidence Interval [95%CI]:1.80–143.6; p = 0.01), and a 6-fold increased risk of having a detectable viremia, independent of antiretroviral treatment (OR:5.47; 95% CI:1.63–18.36; p = 0.006). In vitro , anti-apoA-1 IgG induced dose and time-dependent CD4 + apoptosis that was increased by exposure to HIV RNA. Conclusions In HIV patients, anti-apoA-1 IgG levels are associated with low CD4+ counts, high viremia and a pro-inflammatory systemic profile. Anti-apoA-1 IgG can promote CD4+ lymphocyte apoptosis via undefined pathways.
Databáze: OpenAIRE
Externí odkaz: